Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr160.60 DKK
Change Today +0.80 / 0.50%
Volume 159.0K
LUN On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Stuttgart
OTC US
As of 11:05 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LUN) Snapshot

Open
kr161.30
Previous Close
kr159.80
Day High
kr162.30
Day Low
kr159.20
52 Week High
07/23/15 - kr164.90
52 Week Low
10/14/14 - kr111.50
Market Cap
31.6B
Average Volume 10 Days
210.8K
EPS TTM
kr-2.87
Shares Outstanding
196.6M
EX-Date
03/26/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for H LUNDBECK A/S (LUN)

Related News

No related news articles were found.

h lundbeck a/s (LUN) Details

H. Lundbeck A/S researches, develops, produces, and sells pharmaceuticals for the treatment of brain disorders in Denmark and internationally. The company offers pharmaceutical products for the treatment of schizophrenia, major depressive disorder, symptomatic neurogenic orthostatic hypotension, lennox-gastaut syndrome, and alcohol dependence. It also offers other products for the treatment of Alzheimer’s disease, depression and anxiety, Parkinson’s disease, chorea associated with Huntington’s disease, relapsed indolent B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, manic episodes associated with bipolar 1 disorder, and refractory complex partial seizures. In addition, the company is involved in the development of Brexpiprazole, a novel investigational psychotherapeutic compound; and Idalopirdine, a potent and selective 5-HT6 receptor antagonist that are in Phase III clinical trails. It has strategic alliances with various companies, including Otsuka Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited. The company was founded in 1915 and is headquartered in Valby, Denmark.

5,859 Employees
Last Reported Date: 05/6/15
Founded in 1915

h lundbeck a/s (LUN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LUN) Key Developments

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. Announces US Food and Drug Administration Approves Rexulti (Brexpiprazole) as an Adjunctive Therapy

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced that the US Food and Drug Administration approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder and as a treatment for adults with schizophrenia. Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the US in early August 2015.

H. Lundbeck A/S Presents at Citi European Healthcare Conference, Jun-15-2015

H. Lundbeck A/S Presents at Citi European Healthcare Conference, Jun-15-2015 . Venue: Stirling Square, 5-7 Carlton Gardens, London SW1Y 5AD, United Kingdom. Speakers: Palle Holm Olesen, Chief Specialist of Investor Relations and Vice President of Investor Relations.

H Lundbeck AS Appoints Kare Schultz as President and CEO, Effective as of May 20, 2015

H Lundbeck AS announced the appointment of Kare Schultz as president and CEO, effective as of May 20, 2015. Schultz has an extensive experience in the pharmaceutical industry. He joined Danish drug maker Novo Nordisk in 1989 and was appointed president and chief operating officer (COO) in January 2014. Schultz is also board chairman at Danish brewery group Royal Unibrew A/S and board member at toymaker Lego.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LUN:DC kr160.60 DKK +0.80

LUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ipsen SA €58.52 EUR +1.59
Lupin Ltd 1,697 INR +69.85
Meda AB kr140.80 SEK +0.50
Orion Oyj €38.03 EUR +0.01
Recordati SpA €22.69 EUR +0.56
View Industry Companies
 

Industry Analysis

LUN

Industry Average

Valuation LUN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit www.lundbeck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.